This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Holt, R. I. G. Articles by Citrome, L. Search for Related Content PubMed PubMed Citation Articles by Holt, R. I. G. Articles by Citrome, L. Social Bookmarking                         What's this?

Diabetes and schizophrenia 2005: are we any closer to understanding the link?

Developmental Origins of Health and Disease Division, University of Southampton, Southampton, UK, righ{at}soton.ac.uk

Chris Bushe

Eli Lilly and Company Limited, Basingstoke, UK

Leslie Citrome

New York University School of Medicine, Department of Psychiatry, and the Nathan S Kline Institute for Psychiatric Research and New York University School of Medicine, Orangeburg, NY, USA

The association between schizophrenia and diabetes has been recognized for well over a century, but the underlying reasons for this association are unclear. In October 2003, an international group of diabetologists and psychiatrists met to review the literature relating to the association, and to create pragmatic guidelines for the management of diabetic risk in patients with severe mental illness. Since that meeting, over 100 additional papers have been published on the association between glucose abnormalities and schizophrenia, and this is a clear reflection of the level of interest in this clinically important area. Diabetes is highly prevalent among the schizophrenia population, but most sufferers remain undiagnosed in the community. The reasons why individuals with schizophrenia are more prone to developing diabetes than the general population are poorly defined, but likely to be multifactorial. The role of antipsychotic medications in the development of diabetes and other pre-diabetic states remains controversial, but it appears that the attributable risk is low. Traditional risk factors most probably account for much of the diabetes seen in schizophrenia populations, suggesting that routine screening and aggressive risk factor management are especially important in this patient group.

Key Words: schizophrenia • diabetes • glucose intolerance • antipsychotic drugs

Journal of Psychopharmacology, Vol. 19, No. 6 suppl, 56-65 (2005)
DOI: 10.1177/0269881105058379


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				B. D. Mitchell Editorial: Clustering of Schizophrenia With Other Comorbidities--What Can We Learn? Schizophr Bull, March 1, 2009; 35(2): 282 - 283. [Full Text] [PDF]